Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight

NCT01828554 | Completed Results DMC FDA Drug

• 5 other identifiers: OS12903NCI-2013-012672013-0280A534260SMPH\MEDICINE\HEM-ONC
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to find what happens to capecitabine in the body when dosed using actual versus ideal body weight in subjects with advanced tumors and elevated body mass index.

Conditions

Obesity; Neoplasms

Keywords

Capecitabine pharmacokinetics PK; Elevated Body Mass Index (BMI); Advanced Solid Tumors

Outcome Measures

Primary Outcomes (2)

• Area Under the Curve (AUC) on Cycle 1 Day 1 and Cycle 1 Day 9

  AUC will be calculated for Capecitabine dosed for Ideal Body Weight during the first cycle (days 1-7) and for Capecitabine dosed for Actual Body Weight for first cycle (days 9-15). \[nonlinear mixed effects modeling approach\]

  Up to 15 days

• Cmax During Cycle 1

  Cmax will be reported for Capecitabine dosed for Ideal Body Weight during the first cycle (days 1-7) and for Capecitabine dosed for Actual Body Weight for first cycle (days 9-15). \[nonlinear mixed effects modeling approach\]

  Up to 15 days

Secondary Outcomes (2)

• Response Rate

  Up to 6 months

• Progression Free Survival

  Up to 6 months

Study Arms (1)

Xeloda (Capecitabine)

EXPERIMENTAL

Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using "Ideal Body Weight" to calculate dosage. Cycle 1, Day 8-No drug. Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug. Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage.

Drug: Xeloda

Interventions

Xeloda DRUG

Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using "Ideal Body Weight" to calculate dosage. Cycle 1, Day 8-No drug. Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug. Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage.

Also known as: Capecitabine

Xeloda (Capecitabine)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically or cytologically confirmed advanced or metastatic cancer for which capecitabine treatment is considered a standard treatment option.
• Patients with measurable or evaluable disease are eligible
• Patient's Body Mass Index must be 30 kg/m2 or higher.
• Eastern Cooperative Oncology Group performance status 0-2.
• Age \>18 years.
• Life expectancy of greater than 12 weeks.
• Patients must have adequate organ and marrow function as defined below:
• Hematologic: Absolute Neutrophil Count (ANC) \>1000/mcL (microliters), Hemoglobin \> 8gm/dL (transfusions permitted) and platelets \> 75,000/mcL
• Renal: serum creatinine ≤ upper limit of normal (ULN) or creatinine clearance (CrCl) (either estimated or calculated) \>60 mL/min/1.73 m for patients with creatinine levels above institutional normal.
• Females: Crcl =(140-age)(weight in kg)(0.85)/72 x Serum creatinine
• Males: Crcl =(140-age)(weight in kg)/72 x Serum creatinine
• Hepatic: Serum Bilirubin ≤ 1.5x ULN and No liver metastases: Aspartate aminotransferase(AST) and Alanine transaminase (ALT) ≤ 2.5x ULN Liver metastases: AST and ALT ≤ 5x ULN
• Ability to understand and the willingness to sign a written informed consent document.
• Capecitabine is contra-indicated in pregnant women because of known detrimental effects on the fetus. A negative pregnancy test is required in all premenopausal women within 14 days of study therapy initiation. Women of child-bearing potential and men with an active female sexual partner must agree to use adequate contraception (hormonal, surgical, barrier methods or abstinence allowed) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

You may not qualify if:

• Patients who have had systemic chemotherapies or targeted therapies within 3 weeks or radiotherapy within 2 weeks prior to entering the study or those patients whose adverse events from prior therapies have not recovered to \< grade 1 and are still considered clinically significant.
• Patients receiving any other investigational agents for cancer treatment.
• Patients with treated, stable brain metastases are allowed to enroll. Patients must be at least 4 weeks from brain radiation and off any medications used to treat brain metastases including steroids. Patients are allowed to be on anti-epileptic medications that are not contraindicated based on the drug-interaction table.
• Patients with any condition of the gastrointestinal tract that is expected to result in an inability to swallow or absorb oral medications (ie. prior surgical procedures affecting absorption and requiring i.v. alimentation). This will be determined at the discretion of the PI.
• Patients may not be taking any concomitant drugs that are contraindicated based on the drug-interaction table.
• Concurrent treatment with warfarin (coumadin) is allowed, but close monitoring of the Prothrombin Time/International Normalized Ratio (PT/INR) is recommended.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant or symptomatic cardiac arrhythmia, other malignancies requiring therapy or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women or women who are breastfeeding are excluded from this study because capecitabine is a pregnancy category D drug and is known to pass to the infant in breastmilk.
• Patients with known deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine.

Sponsors & Collaborators

• University of Wisconsin, Madison: lead

Study Sites (1)

University of Wisconsin-Carbone Cancer Center

Madison, Wisconsin, 53792, United States

Location

Related Links

• University of Wisconsin Carbone Cancer Center

MeSH Terms

Conditions

Obesity; Neoplasms

Interventions

Capecitabine

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Results Point of Contact

• Title: Kari B. Wisinski
• Organization: University of Madison Carbone Cancer Center

kbwisinski@medicine.wisc.edu

(608) 262-2876

Study Officials

• Kari B. Wisinski, M.D.

  University of Wisconsin, Madison

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2013
• First Posted: April 10, 2013
• Study Start: June 1, 2013
• Primary Completion: April 1, 2018
• Study Completion: April 1, 2018
• Last Updated: November 25, 2019
• Results First Posted: August 6, 2019

Record last verified: 2019-07

Locations

US (1)